Summary Seventy-two consecutive patients were eligible for a study of clinical determinants of response and response duration in small cell lung cancer (SCLC). Pretreatment values of routine laboratory parameters, and three tumour markers: neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and acidic glycoprotein (AGP) were measured. Descriptive clinical variables as performance status (PS), extent of disease, age and sex were also included in the study. All variables were analysed for influence on the type and duration of response.
Remission rates, response duration and survival time are essential parameters in the assessment of treatment effect in small cell lung cancer (SCLC) .
Increasing interest for identification of factors with influence on the three parameters has emerged during the latest 10 years. Limited disease (LD) is the most essential factor for a good prognosis (0sterlind et al., 1983) . In addition pretreatment performance status and several biochemical parameters have been proved to influence the prognosis.
Recently, the neuronal glycolytic enzyme neuron specific enolase (NSE), has been found in abnormal serum concentrations in more than 75% of patients with SCLC. The concentration of NSE correlates with the extent of disease, but independent of this relationship NSE in itself contributes to the prognosis of the patients (J0rgensen et al., 1988) , albeit the prognostic impact of NSE has not been significant in all investigations (Carney et al., 1982; Akoun et al., 1985; Gronowitz et al., 1990 ).
The present investigation was addressed on the role of NSE as a possible determinant of the probability to obtain complete remission and of overall remission duration. (Peto et al., 1977) . Possible relationships between pretreatment characteristics and response duration were analysed by use of Cox's proportional hazards model (Cox, 1972) . The BMDP PC program (Berkeley, CA, 1990) was used for the analyses. A significance level of P <0.05 was used in all tests. while six had cerebral relapse. One patient was still alive, when the study was closed, while another wanted withdrawal of medication and any follow up until death.
Materials and methods

This investigation included
All variables were analysed for influence on the probability to obtain a complete remission. The CR rates in relation to various clinical and laboratory pretreatment characteristics are shown in Table II . Best CR rates were observed in patients with LD and in patients with normal AGP, while ED, especially with liver involvement, and PS> 1 carried the lowest rate. None of the differences, except for liver metastases, were statistically significant, however.
Results of the life table analyses and log rank tests of relationships between pretreatment characteristics and response duration (CR and PR) are summarised in Table III. Median response duration was 13 and 9 months in CR and PR respectively (Figure 1) . In a separate life table increased NSE values were further categorised (< 50, >50 ng ml-').
Median response durations were 13, 9 and 7 months ( Figure  2) .
The results of the Cox analysis are summarised in Table  IV . NSE and type of response were significantly related to response duration. Extent of disease and PS did not add significant information and were excluded. Other investigated pretherapeutic factors carried lower influence. The proportionality assumption was tested for NSE, type of response, PS, and stage of disease, and was not violated in any of these four variables. Estimation of response duration from the Cox analysis revealed four separate classes with different response time (Figure 3 minants may thus be helpful in the evaluation of treatment response and improve the understanding of clinical variability.
Baseline extent of disease was in our investigation alone an initial response determinant of CR. This importance of extent of disease has previously been stressed. In each of three prognostic groups a higher response rate was found in LD compared with ED (Souhami et al., 1985) . In an investigation, stratified for stage of disease, sex was significantly related to CR probability in both stages, favouring women. Performance status possessed significant relation in ED only (Ostelind et al., 1987) .
In our investigation neither pretreatment NSE nor LDH were response determinants. This lack of critical reference to NSE is refound in other investigations. Akoun et al. (1985) found no significant correlation between initial NSE level and response to chemotherapy by the end of the third month of cytostatic treatment given to 41 SCLC patients. Among 38 LD patients, there was no difference in the response rate between those who initially had a normal NSE and those who presented with high NSE. In 56 ED patients no significant correlation was found between initial serum NSE level and response to therapy (Carney et al., 1982 albeit such a relationship later was proven in two large series from Copenhagen (0sterlind et al., 1987) and Toronto (Sagman et al., 1991) , respectively. NSE was not included in these studies, but a close correlation between LDH and NSE has been shown (J0rgensen et al., 1988) . In numerous investigations (Carney et al., 1982; Akoun et al., 1985; Cooper et al., 1987; J0rgensen et al., 1989; Gronowitz et al., 1990 ) a close correlation between disease extent and NSE was found. The lack of influence of NSE on probability for CR vs that of a PR may partly be caused by the extremely difficult distinction between the responses. This is stressed by the understanding of SCLC as a disseminated disease at presentation with early potential for metastatic dissemination and the stage as a tool facilitating treatment strategy (Idhe et al., 1981) .
Our results corroborate the well established experience that extent of disease has major influence on the probability of CR. The new knowledge derived from this investigation is that NSE, in addition to type of response (CR vs PR), are important determinants of response duration. Consequently, NSE is a relevant laboratory measurement and should be included in future SCLC treatment trials, especially if a secondary randomisation of responding patients should take place. It might aid understanding biological variability and be helpful for comparison of treatment results.
